Article Information
- Received September 29, 2014
- Revision received April 9, 2015
- Accepted April 23, 2015
- First published June 17, 2015.
- Version of record published June 17, 2015.
Author Information
- Jakob Hartmann1,
- Klaus V. Wagner1,
- Steffen Gaali1,
- Alexander Kirschner1,
- Christian Kozany1,
- Gerd Rühter2,
- Nina Dedic1,
- Alexander S. Häusl1,
- Lianne Hoeijmakers1,
- Sören Westerholz1,
- Christian Namendorf1,
- Tamara Gerlach1,
- Manfred Uhr1,
- Alon Chen1,
- Jan M. Deussing1,
- Florian Holsboer1,
- Felix Hausch1, and
- Mathias V. Schmidt1
Author contributions
Author contributions: J.H., G.R., F. Hausch, and M.V.S. designed research; J.H., K.V.W., S.G., A.K., C.K., N.D., A.S.H., L.H., S.W., C.N., T.G., and J.M.D. performed research; S.G., A.K., C.K., G.R., M.U., A.C., F. Holsboer, F. Hausch, and M.V.S. contributed unpublished reagents/analytic tools; J.H., K.V.W., S.G., A.K., C.K., L.H., S.W., C.N., T.G., and M.U. analyzed data; J.H., J.M.D., F. Hausch, and M.V.S. wrote the paper.
Disclosures
- Received September 29, 2014.
- Revision received April 9, 2015.
- Accepted April 23, 2015.
This study was supported by the Max Planck Society. We thank Daniela Harbich, Bianca Schmid, and Anna Mederer for their excellent technical assistance, and Natalie Matosin for proofreading the paper.
A.K., S.G., G.R. and F.H. have filed patent applications for FKBP51 inhibitors. The remaining authors declare no competing financial interests.
- Correspondence should be addressed to either Jakob Hartmann, Felix Hausch, or Mathias V. Schmidt, Max Planck Institute of Psychiatry, Kraepelinstr 2-10, 80804 Munich, Germany. jhartmann{at}psych.mpg.de, hausch{at}psych.mpg.de, or mschmidt{at}psych.mpg.de
Online Impact